Saturday 17 October 2026
Export IRLA’s income statement to Excel — free account
Quince Therapeutics, Inc.
IRLA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 81.9%, free cash flow fell 63.7% and total debt rose 28.2%, each against the same quarter a year earlier.
32.17
1.06
−3.19%
Follow IRLA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.53 | 6.05 | 8.09 | 30.55 | 7.85 | 8.11 | 11.93 | 49.82 | 4.28 |
Net Debt/EBITDA |
0.00 | 0.63 | 2.03 | 1.76 | 1.19 | 1.71 | 2.51 | 5.77 | 0.02 |
Debt/Assets |
19.27% | 12.51% | 8.00% | 0.44% | 0.87% | 0.24% | 0.00% | 0.00% | 92.91% |
Debt/Equity |
(0.50) | 0.48 | 0.16 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | (0.35) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.49 | 0.56 | 0.58 | 0.85 | 0.70 | 0.66 | 0.90 | 0.94 | 0.80 |
Capex/Depreciation |
0.40 | (0.02) | (0.02) | (0.07) | (0.15) | (0.05) | 0.09 | 0.71 | (1.71) |
Interest Coverage |
— | — | — | (48.70) | (145.67) | (38.60) | (17.90) | (12.66) | (6.31) |
| 3,016.49% | (98.63%) | (33.81%) | (47.14%) | (61.85%) | (53.42%) | (89.27%) | 47.16% | 46.25% | |
| (80.75%) | (40.25%) | (23.09%) | (43.57%) | (55.75%) | (48.97%) | (37.50%) | (30.96%) | (30.36%) | |
ROIC |
0.00% | (972.12%) | (92.26%) | (299.21%) | (436.07%) | (126.80%) | (156.78%) | 0.00% | 0.00% |
Return on Tangible Assets |
425.53% | (153.29%) | (46.09%) | (56.72%) | (92.05%) | (63.36%) | (37.78%) | (17.47%) | (207.51%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.73 | 0.52 | 0.48 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(166.77) | (148.69) | (98.61) | (263.29) | (424.71) | (348.66) | (350.13) | (708.75) | (600.24) |
Cash per Share |
70.87 | 188.55 | 403.11 | 538.39 | 718.72 | 917.20 | 1,048.99 | 4,268.81 | 448.06 |
Shareholders Equity per Share |
(142.57) | 139.37 | 456.95 | 600.56 | 798.02 | 1,180.69 | 1,213.00 | (1,942.02) | (1,229.09) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(142.57) | 139.37 | 456.95 | 600.56 | 798.02 | 1,180.69 | 1,213.00 | (1,942.02) | (1,229.09) |
Free Cash Flow |
(41.78) | (32.16) | (18.36) | (44.10) | (63.11) | (50.87) | (33.33) | (11.91) | (9.90) |
Working Capital |
(20.33) | 36.76 | 67.87 | 90.68 | 97.45 | 120.87 | 97.16 | 71.13 | 5.77 |
Capital Expenditures |
(0.35) | (0.26) | (0.07) | (0.06) | (0.18) | (0.05) | (0.05) | (0.21) | (0.08) |
Net Current Asset Value |
(106.34) | (40.30) | (5.38) | 90.43 | 97.03 | 120.66 | 97.16 | (32.92) | (20.46) |
| Other line items | |||||||||
Quick Ratio |
0.41 | 5.60 | 7.84 | 29.38 | 7.51 | 7.87 | 11.23 | 49.22 | 4.19 |
Depreciation/Fixed assets |
(1.47) | 47.52 | 17.96 | 2.33 | 4.65 | 2.26 | (0.88) | (1.06) | 0.37 |
Cash ROIC |
(65,276.56%) | (37.73%) | (10.58%) | (23.06%) | (27.86%) | (16.60%) | (15.48%) | (30.46%) | 173.27% |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(165.37) | (147.50) | (98.24) | (262.91) | (423.50) | (348.31) | (349.55) | (696.13) | (595.58) |
Capex per Share |
(1.41) | (1.19) | (0.38) | (0.38) | (1.21) | (0.36) | (0.58) | (12.62) | (4.67) |
Average Payables |
2.56 | 2.47 | 1.30 | 2.74 | 4.23 | 3.32 | 1.79 | 0.51 | 0.51 |
Average Assets |
104.00 | 141.19 | 135.91 | 118.57 | 161.35 | 156.92 | 98.62 | 40.30 | 40.30 |
Average Common Equity |
(2.78) | 57.62 | 92.84 | 109.59 | 145.42 | 143.87 | 41.43 | (26.45) | (26.45) |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates